RNAM
Avidity Biosciences Inc
NASDAQ · Healthcare · Biotechnology · US
$72.86
+0.05%Year over year
Reported trailing growth
- Revenue
- +72.1%
- EBITDA
- -97.2%
- EBIT
- -96.9%
- EPS
- -71.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +26.7%
- EBITDA
- -97.2%
- EBIT
- -96.9%
- Net income
- —
- EPS
- -72.0%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025